Clinical trial
Escitalopram for the Treatment of Obsessive Compulsive Disorder (OCD)
NCT00116532 · Massachusetts General Hospital, Other · Completed
Key facts
| NCT number | NCT00116532 |
|---|---|
| Title | Escitalopram for the Treatment of Obsessive Compulsive Disorder (OCD) |
| Official title | Escitalopram for the Treatment of Obsessive Compulsive Disorder |
| Lead sponsor | Massachusetts General Hospital, Other |
| Collaborators | Forest Laboratories Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Obsessive Compulsive Disorder |
| Intervention type | Drug |
| Interventions | Escitalopram |
| Enrollment | 30 |
| Start date | Oct 1, 2002 |
| Completion | Feb 1, 2007 |
| First posted | Jun 30, 2005 |
| Last update posted | Apr 24, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: